Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06482853 · ClinicalTrials.gov registry record · Early Phase 1
Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension
A Early Phase 1 study of Obesity and Hypertension, sponsored by Milton S. Hershey Medical Center.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 52
- Enrollment target
- 1
- Study location
NCT06482853: Recruiting Early Phase 1 study of Obesity and Hypertension, sponsored by Milton S. Hershey Medical Center.
NCT06482853 is a Early Phase 1 study of Obesity and Hypertension that is actively recruiting participants, run by Milton S. Hershey Medical Center. The registered enrollment target is 52 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06482853, a Early Phase 1 study of Obesity and Hypertension, is actively recruiting participants, sponsored by Milton S. Hershey Medical Center.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
Obesity is a global health concern that is associated with high blood pressure and an increased risk for developing cardiovascular disease. The purpose of this study is to find out if the investigational drug angiotensin-(1-7) can improve cardiovascular health in people with obesity and high blood pressure.
Primary Outcome
Muscle sympathetic nerve burst rate will be measured continuously using peroneal nerve microneurography during angiotensin-(1-7) versus saline infusion.
Conditions Studied
Interventions
- DRUG Saline
- DRUG Angiotensin-(1-7)
Study Locations (1)
Pennsylvania
- Penn State Milton S. Hershey Medical Center - Hershey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2025-01-23 |
| Est. Completion | 2029-03 |
| Phase | Early Phase 1 |
What NCT06482853 shows while recruiting
NCT06482853 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (94% lower).
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Saline is the first listed.
NCT06482853 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06482853 about?
NCT06482853 is a clinical study titled "Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension". Obesity is a global health concern that is associated with high blood pressure and an increased risk for developing cardiovascular disease. The purpose of this study is to find out if the investigational drug angiotensin-(1-7) can improve cardiovascular health in people with obesity and high blood p...
What is the current status of trial NCT06482853?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 52 participants. The study started on 2025-01-23. Estimated completion is 2029-03.
What conditions does trial NCT06482853 study?
This clinical trial studies the following conditions: Obesity, Hypertension.
What interventions are being tested in trial NCT06482853?
The interventions under investigation include: Saline (DRUG), Angiotensin-(1-7) (DRUG).
Who is sponsoring clinical trial NCT06482853?
This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06482853 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06482853's enrollment target sits among peer trials
52 706th of 1053 higher than 346 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Regional Lipolysis and Adipocyte Lipolysis Protein Stimulation
RECRUITING · Early Phase 1
-
Social Determinants of Sleep and Obesity
RECRUITING · Early Phase 1
-
Effect of Tirzepatide on Markers of MASLD in Patients With Obesity
RECRUITING · Early Phase 1
-
Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues
RECRUITING · Early Phase 1
-
Evaluation of Milk Polar Lipids in Dyslipidemic Adults With Abdominal Obesity
RECRUITING · Early Phase 1
-
Sympathetic Transduction in Obesity-associated Hypertension (OB-HTN)
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI